Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | APG101 |
Synonyms | |
Therapy Description |
APG101, a glycosylated fusion protein comprised of the CD95 extracellular domain and of the IgG1 Fc domain, which binds to CD95L and prevents binding to CD95, potentially leading to decreased tumor cell invasion and increased radiotherapy efficacy (PMID: 29453321, PMID: 25850884, PMID: 22446296). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
APG101 | APG-101|APG 101|Asunercept|Apocept|CAN008|CAN-008 | APG101, a glycosylated fusion protein comprised of the CD95 extracellular domain and of the IgG1 Fc domain, which binds to CD95L and prevents binding to CD95, potentially leading to decreased tumor cell invasion and increased radiotherapy efficacy (PMID: 29453321, PMID: 25850884, PMID: 22446296). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03158389 | Phase Ib/II | Vismodegib Alectinib Idasanutlin Temsirolimus Atezolizumab Palbociclib APG101 | NCT Neuro Master Match - N²M² (NOA-20) (N²M²) | Completed | DEU | 0 |